316 Spring 2023. Volume 1. Number 3 * Corresponding Author: Sussan Moudi Address: Social Determinants of Health Research Center, Health Research Insttute, Babol University of Medical Sciences, Babol, Iran. Tel: +98 (911) 1149817 E-Mail: sussan.mouodi@gmail.com Research Paper Comparison of Glucose Control Profle in Patents With Depression and Type 2 Diabetes Receiving Bupropion or Venlafaxine: A Randomized Controlled Clinical Trial 1. Social Determinants of Health Research Center, Health Research Insttute, Babol University of Medical Sciences, Babol, Iran. 2. Student Research Commitee, Babol University of Medical Sciences, Babol, Iran. Mohammad Ali Bayani 1 , Nikta Nekoofar 2 , Ali Bijanii 1 , *Sussan Moudi 1 Background and Objectve This study aims to compare the efects of bupropion and venlafaxine on glucose control of patents with depression and type 2 diabetes (T2D). Materials & Methods TThis randomized controlled trial was carried out in endocrinology clinic afliated to Babol University of Medical Sciences on adult patents with comorbid T2D and depression in two groups. The frst group (n=19) received venlafaxine 37.5-150 mg daily, while the second group (n=16) was treated with bupropion 75-300 mg per day. The primary outcomes were the severity of depressive symptoms and the glucose control profle. Depressive symptoms were assessed with the Beck depression inventory (BDI). Data was analyzed in SPSS sofware, version 17 package. P<0.05 was considered as statcally signifcant. Results A signifcant decrease in depressive symptoms for both groups was reported, but the diference between the two groups was not statstcally signifcant (P=0.342). Venlafaxine caused a signifcant increase in HbA1c from 7.64 to 8.03 (P=0.04), while bupropion caused a decrease in HbA1c from 7.35 to 7.23 (P=0.06). These changes were signifcantly diferent between the two groups (P=0.028). Conclusion Venlafaxine can reduce depression, but it is not suggested as a proper drug for treatng depression in people with T2D. However, bupropion seems to be a good choice due to its positve efect on depressive symptoms and glycemic control in patents with comorbid T2D and depression. Keywords Depression, Diabetes mellitus, Venlafaxine, Bupropion A B S T R A C T Received: 04 Feb 2023 Accepted: 01 Mar 2023 Available Online: 01 Apr 2023 Citation Bayani MA, Nekoofar N, Bijanii A, Moudi S. [Comparison of Glucose Control Profile in Patients With Depression and Type 2 Diabetes Receiving Bupropion or Venlafaxine: A Randomized Controlled Clinical Trial (Persian)]. Current Psychosomatic Research. 2023; 1(3):316-331. https://doi.org/10.32598/cpr.1.3.32.1 https://doi.org/10.32598/cpr.1.3.32.1 Use your device to scan and read the article online D Extended Abstract Introduction epression is a common comorbidity in pa- tients with diabetes mellitus. A recent sys- tematic review and meta-analysis revealed the prevalence of depression in patients with type 2 diabetes (T2D) as 19%, 1.76 times higher than that of those without diabetes. The prev- alence of T2D is higher in low- and middle-income coun- tries than high-income countries [1]. Multiple biological, social, mental, and lifestyle factors have been reported to be related to depression in diabetic patients [2], which can warn specialists to apply different treatment approaches to achieve better clinical outcomes and improve the qual- ity of life in diabetic patients with depression [3, 4]. Co- morbidity of depression and diabetes can be associated